Biotech company Biogen (NASDAQ: BIIB) will be reporting results this Thursday morning. Here’s what you need to know.

Biogen beat analysts’ revenue expectations by 8.6% last quarter, reporting revenues of $2.43 billion, up 6.1% year on year. It was a satisfactory quarter for the company, with a decent beat of analysts’ EPS estimates but a slight miss of analysts’ full-year EPS guidance estimates.

Is Biogen a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting Biogen’s revenue to decline 5.6% year on year to $2.33 billion, a deceleration from its flat revenue in the same quarter last year. Adjusted earnings are expected to come in at $3.88 per share.

Heading into earnings, analysts covering the company have grown increasingly bearish with revenue estimates seeing 8 downward revisions over the last 30 days (we track 24 analysts). Biogen has missed Wall Street’s revenue estimates twice over the last two years.

Looking at Biogen’s peers in the biotechnology segment, only Incyte has reported results so far. It beat analysts’ revenue estimates by 5.5%, delivering year-on-year sales growth of 16.5%.

Investors in the biotechnology segment have had fairly steady hands going into earnings, with share prices down 1.8% on average over the last month. Biogen is up 3.4% during the same time and is heading into earnings with an average analyst price target of $168.85 (compared to the current share price of $129.80).

Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.